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The known The Australian HPV vaccination program has led to significant declines in a number of HPV-related conditions, including diagnoses of genital warts in young women and heterosexual men at sexual health clinics.
The new We found marked declines in the proportions of young Indigenous women and men attending sexual health clinics for the first time who were diagnosed with genital warts following introduction of the HPV vaccination program, similar to declines among non-Indigenous young women and men.
The implications Sustained high HPV vaccine coverage rates and monitoring are needed to close the gap between Indigenous and non-Indigenous Australians in the rates of cervical and other HPV-related cancers in older women.
T he Australian national human papillomavirus (HPV) vaccination program commenced in April 2007. Free vaccination was provided to 12e13-year-old girls in schools; this was supplemented by a 3-year catch-up program for 13e18-year-old girls in schools and for 18e26-year-old women through family doctors in July 2007. 1 In 2013, boys were added to the program, providing free HPV vaccination to 12e13-year-old boys in schools and, for 2 years, a catch-up program for 14e15-year-old boys. Australia uses the quadrivalent HPV vaccine (Gardasil), protecting against HPV types 6 and 11, which cause ano-genital warts, and HPV types 16 and 18, which cause cancer. 2, 3 The Australian HPV vaccination program has had very promising results. High coverage rates among vaccine-eligible girls have been achieved, 73% receiving all three doses in 2010. 4 Significant reductions in the prevalence of HPV-related conditions have been seen; diagnoses of genital warts in young women and heterosexual men at sexual health clinics, 5, 6 inpatient treatment of genital warts at private hospitals, 7 hospital admissions for genital warts, 8 the prevalence in young women of HPV types targeted by the quadrivalent vaccine, 9,10 and the incidence of high grade cervical abnormalities 11 have all declined.
Measuring the impact of the HPV vaccination program in Aboriginal and/or Torres Strait Islander (Indigenous) people is important because cervical cancer rates among Indigenous women are twice as high as among non-Indigenous women. 12 Similar findings have been reported overseas; a meta-analysis of data from 35 studies found that indigenous women had elevated risks of invasive cervical cancer and related mortality (pooled risk ratios, 1.72 and 3.45 respectively). 13 Indigenous Australians experience poorer outcomes than non-Indigenous people for a range of conditions, 14 including some sexually transmissible infections (STIs). [15] [16] [17] In response to these inequities, the Australian Government initiated the Closing the Gap program in 2008, 18 followed in 2014 by the Fourth National
Aboriginal and Torres Strait Islander Blood-borne Viruses and STI Strategy, 2014e2017, which includes the aim of achieving high rates of HPV vaccination. 19 Despite their disproportionately high rates of cervical cancer, there is a lack of information on HPV vaccination and its impact, including on the prevalence of genital warts, in indigenous populations around the world. A recent systematic review 20 did not find any studies that reported the effect of HPV vaccination programs in indigenous populations. The aim of our study was therefore to examine the effect of the HPV vaccination program on diagnoses of genital warts in Indigenous Australians, and to compare this with data for non-Indigenous Australians.
Methods
Routinely collected de-identified data were collated from 39 clinics in the Genital Warts Surveillance Network Design, setting, participants: Analysis of routinely collected data from patients attending 39 sexual health clinics (SHCs) in the Genital Warts Surveillance Network for the first time.
Major outcome: The average annual proportion of Indigenous and non-Indigenous SHC patients diagnosed with genital warts during the pre-vaccination (2004e2007) and vaccination periods (2008e2014), stratified by age group and sex.
Results: 7.3% of the 215 599 Australian-born patients with known Indigenous status and seen for the first time at participating SHCs during 2004e2014 were Indigenous Australians. The average proportion of female Indigenous patients diagnosed with warts was lower during the vaccination period than during the pre-vaccination period (in those under 21, summary rate ratio [SRR], 0.12; 95% CI, 0.07e0.21; P < 0.001); in 21e30eyear olds: SRR, 0.41; 95% CI, 0.27e0.61; P < 0.001); there was no significant difference for women over 30 (SRR, 0.84; 95% CI, 0.51e1.36; P ¼ 0.47). The proportion of male Indigenous heterosexual SHC patients under 21 diagnosed with warts was also lower during the vaccination period (SRR, 0.25; 95% CI, 0.12e0.49; P < 0.001), with no significant changes among older Indigenous men over 30.
Conclusions: There were marked declines in the proportions of diagnoses of genital warts in young Indigenous women and men attending SHCs after the introduction of the HPV vaccination program. If high levels of HPV vaccine coverage are sustained, HPV-related cancer rates should also decline.
(http:/ /kirby.unsw.edu.au/projects/genital-warts-surveillancenetwork). The network, including 47% of all sexual health clinics in Australia, was established in 2008 to measure the effects of the Australian HPV vaccination program on the prevalence of genital warts. The participating clinics, all of which have computerised medical records systems, are the largest such clinics by patient volume, accounting for more than 90% of all sexual health clinic consultations in Australia. Patient demographic and behavioural data (age, sex, Indigenous status, country of birth, sex of their sexual partners) and data on the clinical diagnosis of genital warts were collated.
Data analysis
Australian-born patients who attended one of the clinics for the first time between January 2004 and December 2014 were included in the study. Analysis was restricted to Australian-born patients because the HPV vaccine is available free of charge only to Australian permanent residents and citizens (residency status is not routinely collected at clinics), and to first visits to exclude patients with recurrent genital warts diagnoses. Patients of unknown Indigenous status were excluded. Men who reported having sex only with men or with both men and women in the past 12 months were classified as men who have sex with men (MSM), and men who reported having sex only with women as heterosexual.
The study period was divided into a pre-vaccination period (2004e2007) and a vaccination period (2008e2014). All data from 2007 were included in the pre-vaccination period. The proportion of patients diagnosed with genital warts was calculated by dividing the number of new diagnoses by the number of patients seen, and the relative percentage change in proportion over time was calculated.
The pattern of change in diagnoses was described using univariate Poisson regression models, with the number of diagnoses as the outcome and the calendar year as the independent variable. Results are presented as average annual trends (average annual proportional change in rates; eg, for 10% average increase, average annual trend ¼ 1.10). Models were separately fitted for the prevaccination and vaccination periods; the pre-vaccination period was assessed to identify any changes related to factors other than vaccination. Model fit was assessed in Pearson c 2 tests and by visually comparing it with the observed proportions (online Appendix, figures 1e3).
The average difference between the pre-vaccination and vaccination periods in the proportions of patients diagnosed with genital warts was analysed in univariate Poisson models, with the number of diagnoses as the outcome and the vaccination period as the binary independent variable. Results are presented as summary rate ratios (SRRs).
The magnitude of the difference between Indigenous and nonIndigenous people in rate change was quantified in a bivariate Poisson model, using the number of diagnoses as the outcome, including an interaction term for Indigenous status and year. Results are presented as the ratio of the SRRs for diagnoses in nonIndigenous and Indigenous people to account for potential differences in patient numbers by vaccination period for each group.
A sensitivity analysis that excluded the 2007 data was conducted with the same methods to allow a wash-in period for the intervention. Results were qualitatively compared with those of the primary analyses to assess any reduction in the proportion of diagnoses during 2007 associated with vaccinations during the second half of 2007.
Analyses for three age groups were conducted: people under 21 (all women in this age group were eligible to receive free HPV vaccination, but boys aged 12e15 years were only eligible to receive it from early 2013), people aged 21e30 years (most women in this age group were eligible to receive free HPV vaccination, and all women by the end of the study period), and those over 30 (few women in this age group were eligible to receive free HPV vaccination). No men over 21 had been eligible for free vaccination at any time. Analyses for MSM were not stratified by age because of the small number of observations. All analyses were conducted in Stata 13.1 (StataCorp). Ratio of SRRs. The reduction in the proportion of clinic patients diagnosed with genital warts associated with the vaccination period was similar for Indigenous and non-Indigenous women, and the fall was significantly greater only for Indigenous women under 21 (SRR ratio, 1.72; 95% CI, 1.72e2.91; P ¼ 0.043) (Box 2).
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Heterosexual men
The rates of diagnosis of genital warts were consistently lower for Indigenous men than Australian-born non-Indigenous men in each age group (Box 3; online Appendix, table 2).
Average annual trend. There was an increase in annual diagnosis rates during the pre-vaccination period for both Indigenous and non-Indigenous men under 21 (each P < 0.05), but no statistically significant change for those aged 21e30 years, nor for Indigenous men over 30. There was, however, a decline in rate for non- Indigenous men over 30 during this period (P ¼ 0.001). During the vaccination period, there was no change in diagnosis rates among younger Indigenous men but a decline in those over 30 (P ¼ 0.04). There was a decline in diagnosis rates among all non-Indigenous men, with the greatest decline among those under 21 (P < 0.001) (Box 2).
Vaccination v pre-vaccination periods. The average annual rates of diagnosis were statistically significantly lower during the vaccination period than the pre-vaccination period for younger Indigenous men (SRR for Indigenous men under 21, 0.25; 95% CI, 0.12e0.49; P < 0.001; for 21e30-year-old men, 0.56; 95% CI, 0.35e0.90; P ¼ 0.016), but not for those over 30; the reductions were significantly lower for all non-Indigenous men (SRR for nonIndigenous men under 21, 0.33; 95% CI, 0.28e0.39; P < 0.001; for 21e30-year-old men, 0.60; 95% CI, 0.56e0.63; P < 0.001; for those over 30, 0.83; 95% CI, 0.78e0.89; P < 0.001) (Box 2).
Ratio of SRRs.
The level of change in the proportion of clinic patients diagnosed with genital warts associated with the vaccination period was similar for Indigenous and non-Indigenous men in all age groups (Box 2).
Men who have sex with men
The rates of diagnosis of genital warts were similar for Indigenous and non-Indigenous MSM (Box 4; online Appendix, table 3).
Average annual trends. There was no trend in the diagnosis rates for Indigenous or non-Indigenous MSM during the pre-vaccination period. Similar reductions in rate were measured in both groups during the vaccination period, but the change was not statistically significant for Indigenous MSM (Box 2).
Vaccination v pre-vaccination periods. There was no significant change in the average annual rate of diagnosis for Indigenous MSM (SRR, 0.74; 95% CI, 0.40e1.36; P ¼ 0.33), but the rate declined significantly among non-Indigenous MSM (SRR, 0.64; 95% CI, 0.59e0.70; P < 0.001) (Box 2).
Ratio of SRRs. The reduction in the proportion of MSM diagnosed with genital warts associated with the vaccination period was not significantly different for Indigenous and non-Indigenous men (Box 2).
Sensitivity analysis
The results of the sensitivity analysis were qualitatively similar to those of the primary analysis. Trend results were attenuated by the reduced time frame and need to be interpreted with caution, but there was no significant downward trend in rate during the prevaccination period. SRRs were similar to those in the primary analysis, but were influenced slightly by the reduced time frame (online Appendix, tables 4 and 5).
Discussion
We found that there have been marked declines since the introduction of the national HPV vaccination program in the proportions of Indigenous and non-Indigenous women under 21 attending sexual health clinics for the first time who are diagnosed with genital warts. The decline for Indigenous women under 21 was higher than for non-Indigenous women of the same age. Marked decreases were also found for young Indigenous heterosexual men and non-Indigenous heterosexual men of all ages. The decline in heterosexual men is probably due to herd protection, as it is too early to expect any substantial direct effect of the vaccination of boys. The declines in the proportions of diagnoses in older Indigenous men were not statistically significant, probably because of the small number of patients in this group (online Appendix, table 2).
The reductions in the proportions of Indigenous and nonIndigenous young people attending sexual health clinics diagnosed with genital warts are remarkable; in recent times, very few interventions have achieved such dramatic declines in an STI, with the exception of donovanosis. 16 While the number of genital warts diagnoses has been declining since 2007, those of chlamydia has been increasing. Data from the Australian Collaboration of Coordinated Enhanced Sentinel Surveillance study, which includes the same clinics as our study, reported that the proportion of Indigenous women attending these clinics who were chlamydia-positive had risen from 14 21 We found no significant difference between the rates of decline in genital wart diagnoses in Indigenous and non-Indigenous women -except among those under 21, for whom the decline was greater among Indigenous women -nor between those for Indigenous and non-Indigenous heterosexual men or MSM. In contrast, data from the HPV vaccination catch-up program for Indigenous women in Queensland and Northern Territory indicated that coverage rates were lower among Indigenous women than non-Indigenous women in Queensland, particularly for the third dose; in the Northern Territory in 2011, however, completion rates for the three doses were similar for the two populations. 22 The clinics included in our study included only a subset of Indigenous people in each state and territory, so it is possible that some differences may have been masked.
The proportion of MSM diagnosed with genital warts declined significantly among non-Indigenous but not among Indigenous patients. MSM presumably do not benefit from the herd protection achieved by the HPV vaccination program, and the decline in the diagnosis rate among non-Indigenous MSM is probably explained by the increasing number of MSM seen at sexual health clinics in the past decade (Appendix, table 3). MSM have been encouraged to attend sexual health clinics more frequently for asymptomatic screening, whereas asymptomatic Indigenous men have always been a priority population. 23 This study has several strengths. First, it is the first to examine trends in the diagnoses of genital warts in Indigenous people attending sexual health clinics. Second, these data come from a national surveillance network with wide geographic coverage. Third, retrospective data were available, so we could compare the number of diagnoses of genital warts during the vaccination and pre-vaccination periods. There are three main limitations to our study. First, it was an ecological study, and the falls in the proportions of clinic patients diagnosed with genital warts cannot be directly attributed to the HPV vaccination program. However, the sudden fall in diagnosis rates after its commencement and the doseeresponse relationship (that is, the number of diagnoses of genital warts fell as the number of people vaccinated increased) support a causal association. Second, the Indigenous patients included in our study are not representative of all Indigenous people because sexual health clinics see patients who are at higher risk of STIs than the general population; 24 for some states a smaller proportion of Indigenous people was included, so that there may be local differences; and many Indigenous people receive health care from the Aboriginal and Community Controlled Health Services and other primary health services. 25 Third, the numbers of patients in some groups were small, so that the 95% CIs for trends and SRRs were wide.
Current levels of HPV vaccination coverage among young Indigenous Australians of vaccine-eligible age are providing them with the same benefit as non-Indigenous Australians, closing the gap with respect to genital warts in young women. Older Indigenous women still have disproportionately high rates of cervical pathology and cancer, so that cervical cancer screening coverage for these women should be increased. Sustaining high HPV vaccination rates and monitoring coverage in Indigenous communities should also close the gap for cervical and other HPV-related cancers.
